https://peptide.zone/story/employer-glp-1-coverage-stalls-kff-surveyPeptide Zoneen2026-10-27T15:51:00.000ZEmployer GLP 1 coverage for weight loss stalls at 18 percent in KFF survey https://peptide.zone/story/wada-2027-prohibited-list-glp-1-permittedPeptide Zoneen2026-10-27T15:41:00.000ZWADA 2027 Prohibited List keeps semaglutide and tirzepatide permitted for athletes https://peptide.zone/story/peptide-injectors-needle-programs-safety-advicePeptide Zoneen2026-10-27T14:58:00.000ZPeptide injectors need needle programs and safety advice say Queensland researchers https://peptide.zone/story/topical-icotrokinra-preclinical-psoriasis-dataPeptide Zoneen2026-10-27T14:22:00.000ZDong A ST presents topical icotrokinra data from early skin and animal tests https://peptide.zone/story/jama-peptide-compounding-vote-fdaPeptide Zoneen2026-10-26T17:30:00.000ZJAMA Viewpoint warns peptide compounding vote threatens the FDA approval system https://peptide.zone/story/elecoglipron-kidney-data-solsticePeptide Zoneen2026-10-26T16:36:00.000ZElecoglipron kidney data from SOLSTICE support a 7000 patient phase 3 outcomes trial